Perrigo Company plc

Good evening and welcome to Perigo's third quarter 2020 financial results conference call. All participants will be in a listen-only mode. Should you require assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press the star, then the one on your telephone keypad. To withdraw your question, please press stars and two. Please note, this event is being recorded. I would now like to hand the conference over to Mr. Bradley Joseph, Vice President, Investor Relations and Corporate Communications. Please go ahead.

Thank you and welcome everyone to Perigo's third quarter 2020 earnings conference call. We hope everyone is healthy and safe. I hope that you've had a chance to review the earnings and judicial review press releases we issued earlier today. A copy of the releases and the presentation for today's earnings discussion are available within the investor section of the perigo.com website. Joining today's call are President and CEO Murray Kessler and CFO Ray Silcock. I'd like to remind everyone that during this call, participants will make certain forward-looking statements Please refer to the important information for shareholders and investors and safe harbor language regarding these statements in our earnings press release. A few items to highlight before we get started. When discussing the business, Murray will reference only non-GAAP adjusted numbers for the quarter unless otherwise noted. All comparisons of operating results against prior year periods include the previously disclosed third quarter 2019 net sales adjustments for the market withdrawal of renitidine, as well as operating results attributable to the 2019 held-for-sale animal health business previously included in the Consumer Self-Care America segment. Comparisons to prior periods also exclude, one, divested businesses, which includes contributions from the divested animal health business and the divested Rosemont business and Canaderm product, both previously included in the Consumer Self-Care International segment.

And two, currency.